Developer docs
API playgroundTry for free, no card

Search company profiles

Waiv

Full company profile

uuid0000g9f

Namestring
Waiv
Legal namestring
Waiv
Websiteurl
wearewaiv.com
Company typeenum
Private
Founded yearint
2026
Descriptiontext

Waiv is a Paris-based AI precision medicine company that develops and commercializes clinical-grade digital pathology tests for oncology, spun out of Owkin in March 2026. The company's core product is the Destra platform, an AI-native SaaS infrastructure that delivers a portfolio of diagnostic tests analyzing routine H&E and IHC stained whole slide images: RlapsRisk BC (CE-IVD marked breast cancer relapse risk profiling with C-index 0.81), MSIntuit Suite / MSIntuit CRC (CE-IVD marked microsatellite instability screening for colorectal, endometrial, and gastric cancers with 96-98% sensitivity), BRCAura (germline BRCA1/2 mutation prediction with 80% AUC), and TLS Detect (97%-sensitivity tertiary lymphoid structure detection, research use). The technology is built on proprietary foundation models, notably the Phikon-v2 vision transformer pre-trained on 460 million pathology tiles across 30+ cancer types and a distilled H0-mini model, with the platform interoperable with Proscia, Roche Diagnostics, Sectra, and Tribun Health IMS/viewer systems.

Waiv serves two primary customer segments: hospital pathology labs and diagnostic organizations, which deploy Waiv tests either directly through the Destra platform or embedded within existing IMS workflows, and pharmaceutical and biotech companies, which engage Waiv for biomarker discovery, patient stratification, and companion diagnostic co-development under multi-year collaboration agreements. Named biopharma partners include MSD (Merck & Co.), AstraZeneca, and Daiichi Sankyo. The revenue model combines enterprise subscription licensing for clinical diagnostic tests with professional services revenue from biopharma R&D collaborations, milestone payments, and potential downstream royalties on companion diagnostics.

The company was incorporated as Owkin Dx, a French société par actions simplifiée, and operates from its Paris headquarters at 14-16 Boulevard Poissonnière. Following the 2026 spinout, Waiv is led by CEO and Co-Founder Meriem Sefta and Co-Founder Lionel Guillou, with Owkin retaining a minority equity stake and a strategic partnership for continued access to the parent's hospital data network and foundational research. Total disclosed funding is $35 million, raised across a $33 million initial financing round co-led by OTB Ventures and Alpha Intelligence Capital in March 2026 and a $2 million follow-on from CRB Health Tech in April 2026.

Short descriptiontext

Waiv is a Paris-based AI digital pathology company delivering CE-IVD marked precision oncology tests from H&E slides to hospital pathology labs and pharmaceutical partners. Spun out of Owkin in 2026, it operates its Destra platform and proprietary foundation models for prognostic, MSI, and BRCA screening.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital pathology software, AI precision diagnostics, oncology biomarker testing, computational pathology platform, medical imaging AI
Industry4 codes
PRIMARYHLAAALAI
Cytology & Histopathology Diagnostics (IHC, ISH, tissue-based assays)
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
NAICS code3 codes
  • Medical and Diagnostic Laboratories6215
  • Analytical Laboratory Instrument Manufacturing334516
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Precision Oncology Digital Pathology AI Diagnostics
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Clinical diagnostic test licensing and deployment
TypeSubscription Recurring
Description

Waiv commercializes CE-IVD marked AI precision tests (RlapsRisk BC, MSIntuit CRC) to hospital pathology labs, diagnostic organizations, and healthcare providers through its Destra platform or integrated into existing IMS/viewer systems. Revenue generated through test licensing subscriptions or per-test fees deployed via SaaS platform.

wearewaiv.com
2Biopharma companion diagnostics and biomarker discovery partnerships
TypeProfessional Services
Description

Waiv collaborates with pharmaceutical companies (MSD, AstraZeneca, Daiichi Sankyo) on AI-driven biomarker discovery, patient stratification, and companion diagnostic development for drug programs. Revenue from R&D collaboration fees, milestone payments, and potential royalties on companion diagnostics developed alongside drug programs.

wearewaiv.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Pricing details2 tiers
1Enterprise lab and healthcare provider licensing
ModelSubscriptionBilling cadenceAnnual
Notes

Access to Waiv AI precision tests via Destra platform or integrated IMS deployment. Pricing determined through enterprise agreements, not publicly listed.

wearewaiv.com
2Pharmaceutical R&D and biomarker discovery collaboration
ModelHybridBilling cadenceMulti-year contract
Notes

R&D collaboration fees, milestone payments, and potential downstream royalties on companion diagnostics developed for drug programs.

wearewaiv.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 5 records shown
1Destra
Description

AI-native digital pathology platform built for clinical workflows that delivers Waiv's best-in-class AI precision tests into pathologists' hands.

wearewaiv.com
+4 more records
Core offering1 text field

Waiv develops and commercializes CE-IVD marked AI-powered precision diagnostic tests for oncology, analyzing digitized H&E and IHC whole slide images to deliver prognostic risk profiling, MSI screening, BRCA mutation prediction, and tertiary lymphoid structure detection. Its product suite includes the Destra SaaS platform, RlapsRisk BC (breast cancer prognosis), MSIntuit Suite/CRC (MSI screening), BRCAura (gBRCA mutation screening, research use), and TLS Detect (research-use deep learning tool). The company also provides biopharma R&D services for biomarker discovery and companion diagnostic development.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • RlapsRisk BC achieves C-index of 0.81 vs 0.76 for clinical factors alone, with cumulative sensitivity of 0.69 vs 0.63 and dynamic specificity of 0.80 vs 0.76 compared to clinical factors alone for 5-year MFS prediction.
+4 more records
Product overview1 text field

Waiv is an AI precision testing company that has spun out from Owkin (formerly Owkin Dx), building on seven years of medical-AI research to deliver clinical-grade, AI-powered diagnostic tests for precision oncology. The company operates a platform-plus-products architecture centered on its Destra digital pathology platform, which delivers multiple clinically validated AI tests including RlapsRisk BC (breast cancer prognosis), MSIntuit Suite (MSI screening for colorectal, endometrial, and gastric cancers), BRCAura (gBRCA mutation screening), and TLS Detect (tertiary lymphoid structures detection). Products leverage foundation models trained on hundreds of thousands of histopathology images from an international data network spanning academic institutions, hospitals, and laboratories. The portfolio includes both CE-IVDR marked clinical diagnostics and research-use-only products, with commercial deployment via Destra's interoperable platform and partnerships with pharmaceutical companies including MSD, AstraZeneca, and Daiichi Sankyo for biomarker discovery and companion diagnostics.

Product and service6 records
1Destra Platform
CategoryDigital pathology platform
Description

AI-native digital pathology SaaS platform that delivers Waiv's AI precision tests (RlapsRisk BC, MSIntuit Suite, BRCAura) into pathologist workflows. Provides interoperable access via API and through integrations with Proscia, Roche Diagnostics, Sectra, and Tribun Health viewer/IMS systems, with clinically compliant outputs and scalable SaaS infrastructure.

2RlapsRisk BC
CategoryClinical AI diagnostic test
Description

CE-IVDR marked AI precision test that predicts breast cancer relapse risk directly from standard digitized H&E histopathology slides and clinical data, delivering genomic-level risk profiling without extensive additional molecular testing. C-index of 0.81 vs 0.76 for clinical factors alone. For hospital pathology labs and breast cancer treatment decision-making.

3MSIntuit Suite (including MSIntuit CRC)
CategoryClinical AI diagnostic test
Description

CE-IVDR marked AI-enabled MSI (Microsatellite Instability) screening test suite that operates on H&E stained slides across colorectal, endometrial, and gastric cancers. Sensitivity 0.96-0.98 and specificity 0.47-0.46, designed to rule out approximately half of non-MSI patients from further testing. For pathology labs needing rapid, scalable MSI pre-screening to accelerate access to targeted immunotherapies.

4BRCAura RUO
CategoryResearch AI diagnostic test
Description

Research-use-only AI digital pathology test designed to identify germline BRCA1/2 mutations from routine histology slides of HR+/HER2- breast cancer. AUC of 80% with 93% sensitivity, able to rule out approximately 40% of patients unlikely to carry gBRCA mutations. For research and translational research use.

5TLS Detect
CategoryResearch AI diagnostic test
Description

Deep learning software that detects Tertiary Lymphoid Structures (TLS) from digitized H&E whole slide images across tumor types. Sensitivity of 97% on external validation, providing prognostic insights and predictive biomarkers for immunotherapy response, delivered via PDF report and dynamic heatmap. For research use only.

6Biopharma Solutions
CategoryBiopharma services
Description

End-to-end computational pathology services for pharmaceutical and biotech partners covering biomarker discovery, tumor microenvironment analysis across H&E and IHC, AI-derived outcome prediction, and co-development of companion diagnostics for oncology drug and ADC programs. For pharmaceutical development teams seeking biomarker and patient stratification support.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-06
Description

Collaboration under which Waiv applies its end-to-end computational pathology platform to Daiichi Sankyo's antibody-drug conjugate (ADC) program. Waiv will perform tumor microenvironment (TME) analysis across H&E and IHC stained samples, biomarker discovery, and outcome prediction aimed at identifying biomarkers of treatment response for early-phase clinical trial optimization.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-02-27
Description

Waiv spun out from Owkin as an independent company. Owkin retains a minority stake without operational governance involvement. Waiv remains a strategic partner in Owkin's patient validation ecosystem, leveraging Owkin's decade of foundational medical AI research, patient data network of over 800 hospitals, and hospital partnerships.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-02
Description

Partnership to develop an AI gBRCA pre-screen solution for breast cancer, building on prior Owkin collaboration on BRCAura. AstraZeneca collaborated on BRCAura development to accelerate identification of BRCA mutations for targeted treatment decisions. Owkin's K Pro platform was used under a separate multi-year licensing agreement.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-12-19
Description

Collaboration agreement to develop and commercialize AI-powered digital pathology diagnostics for the EU market. Waiv collaborates with MSD to assess the clinical impact of MSIntuit CRC. MSD is an existing pharmaceutical partner for biomarker discovery and AI-guided precision testing.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

World-class cancer research institute in Villejuif, France, and co-developer of RlapsRisk BC and BRCAura. Gustave Roussy contributed patient data for RlapsRisk BC validation and BRCAura development. Part of Waiv's network of academic partners contributing to clinical validation studies.

6Institut Bergonié
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Comprehensive Cancer Center in Bordeaux, France. Development partner for TLS Detect, contributing annotated data for deep learning model development. Also contributing data for MSI Pan-Tumor Dx project and clinical validation studies.

wearewaiv.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Leading French academic cancer research center in Paris. Academic partner in the RlapsRisk BC validation study under the Unicancer network. Contributed patient data for clinical validation of Waiv's diagnostic tests.

8Unicancer
Strategic tierCoreTypeStrategic or Co-development Partner
Description

French academic cancer research network acting as data controller for the RlapsRisk BC validation study. Coordinates academic hospital data sharing across the French hospital network for Waiv's clinical validation studies.

wearewaiv.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Precision oncology research collaboration announced between Owkin and 4baseCare to advance inclusive precision oncology research, jointly pursuing research initiatives.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

PathAI develops AI-powered pathology diagnostics for oncology and provides biopharma services for biomarker discovery and clinical trial support, directly mirroring Waiv's dual clinical-product and pharma-services model with overlapping H&E-based biomarker targets.

TypeDirect peer
Description

Paige offers AI-based digital pathology products including FDA-cleared prostate cancer detection and enterprise pathology platforms; serves biopharma for biomarker and companion diagnostic development with similar foundation-model-based histology analysis to Waiv.

TypeDirect peer
Description

Ibex provides AI-powered cancer diagnostics deployed in clinical pathology workflows, including breast and prostate cancer detection, with similar H&E-based tissue analysis value proposition and integration with IMS systems.

TypeDirect peer
Description

ArteraAI develops AI-based multimodal prostate cancer prognosis and treatment-decision tests from H&E slides with FDA clearances; directly comparable to Waiv's RlapsRisk BC breast cancer prognostic product in clinical AI biomarker prediction from routine pathology.

TypeDirect peer
Description

Proscia is a digital pathology platform that distributes AI applications including Waiv's through its Concentriq IMS; comparable as both an integration channel and a competitor developing its own AI pathology applications.

TypeBroad incumbent
Description

Owkin is Waiv's parent company, a broader AI biotech providing federated learning, drug discovery, and diagnostic services; retains minority stake in Waiv and remains its data and hospital network partner across oncology biomarkers.

TypeBroad incumbent
Description

Sectra provides enterprise imaging and pathology IMS platforms used by hospitals; while a distribution partner for Waiv tests, its installed base and AI strategy position it as a broader incumbent in the pathology IT stack.

8Tempus AI
TypeBroad incumbent
Description

Tempus operates a broad precision medicine platform combining molecular diagnostics, multimodal data, and AI for oncology; competes with Waiv's biopharma services and biomarker discovery offerings from a much larger installed base.

TypeBroad incumbent
Description

Roche is both a Waiv distribution partner and a major incumbent in IVD and digital pathology with the navify Digital Pathology platform; comparable as an established player whose installed base could either accelerate or compete with Waiv's AI tests.

TypeEmerging player
Description

Mindpeak offers AI image analysis solutions for pathology including IHC quantification and biomarker scoring, with overlapping technology in tissue-based AI diagnostics; smaller scale than Waiv but directly competitive on certain use cases.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration5 records

Each record includes

Title, Type, Description, Source

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds18 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors18 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Waiv

Precision Oncology Digital Pathology AI Diagnosticswearewaiv.com

Waiv is a Paris-based AI digital pathology company delivering CE-IVD marked precision oncology tests from H&E slides to hospital pathology labs and pharmaceutical partners. Spun out of Owkin in 2026, it operates its Destra platform and proprietary foundation models for prognostic, MSI, and BRCA screening.

What Waiv does

Waiv is a Paris-based AI precision medicine company that develops and commercializes clinical-grade digital pathology tests for oncology, spun out of Owkin in March 2026. The company's core product is the Destra platform, an AI-native SaaS infrastructure that delivers a portfolio of diagnostic tests analyzing routine H&E and IHC stained whole slide images: RlapsRisk BC (CE-IVD marked breast cancer relapse risk profiling with C-index 0.81), MSIntuit Suite / MSIntuit CRC (CE-IVD marked microsatellite instability screening for colorectal, endometrial, and gastric cancers with 96-98% sensitivity), BRCAura (germline BRCA1/2 mutation prediction with 80% AUC), and TLS Detect (97%-sensitivity tertiary lymphoid structure detection, research use). The technology is built on proprietary foundation models, notably the Phikon-v2 vision transformer pre-trained on 460 million pathology tiles across 30+ cancer types and a distilled H0-mini model, with the platform interoperable with Proscia, Roche Diagnostics, Sectra, and Tribun Health IMS/viewer systems.

Waiv serves two primary customer segments: hospital pathology labs and diagnostic organizations, which deploy Waiv tests either directly through the Destra platform or embedded within existing IMS workflows, and pharmaceutical and biotech companies, which engage Waiv for biomarker discovery, patient stratification, and companion diagnostic co-development under multi-year collaboration agreements. Named biopharma partners include MSD (Merck & Co.), AstraZeneca, and Daiichi Sankyo. The revenue model combines enterprise subscription licensing for clinical diagnostic tests with professional services revenue from biopharma R&D collaborations, milestone payments, and potential downstream royalties on companion diagnostics.

The company was incorporated as Owkin Dx, a French société par actions simplifiée, and operates from its Paris headquarters at 14-16 Boulevard Poissonnière. Following the 2026 spinout, Waiv is led by CEO and Co-Founder Meriem Sefta and Co-Founder Lionel Guillou, with Owkin retaining a minority equity stake and a strategic partnership for continued access to the parent's hospital data network and foundational research. Total disclosed funding is $35 million, raised across a $33 million initial financing round co-led by OTB Ventures and Alpha Intelligence Capital in March 2026 and a $2 million follow-on from CRB Health Tech in April 2026.

Waiv firmographics

Firmographics
Name
Waiv
Legal name
Waiv
Website
https://wearewaiv.com
Company type
Private
Founded year
2026
Operating status
Operating
Headcount range
251–500 employees
Short description
Waiv is a Paris-based AI digital pathology company delivering CE-IVD marked precision oncology tests from H&E slides to hospital pathology labs and pharmaceutical partners. Spun out of Owkin in 2026, it operates its Destra platform and proprietary foundation models for prognostic, MSI, and BRCA screening.
Ownership category
akta.pro rank

Waiv industry classification

Industry
Product category
Precision Oncology Digital Pathology AI Diagnostics
NAICS
Medical and Diagnostic Laboratories (6215), Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAALAI
Cytology & Histopathology Diagnostics (IHC, ISH, tissue-based assays)
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

Keywords

  • Digital pathology software
  • AI precision diagnostics
  • Oncology biomarker testing
  • Computational pathology platform
  • Medical imaging AI

Where Waiv is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Waiv business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Clinical diagnostic test licensing and deployment: Waiv commercializes CE-IVD marked AI precision tests (RlapsRisk BC, MSIntuit CRC) to hospital pathology labs, diagnostic organizations, and healthcare providers through its Destra platform or integrated into existing IMS/viewer systems. Revenue generated through test licensing subscriptions or per-test fees deployed via SaaS platform.
  2. Biopharma companion diagnostics and biomarker discovery partnerships: Waiv collaborates with pharmaceutical companies (MSD, AstraZeneca, Daiichi Sankyo) on AI-driven biomarker discovery, patient stratification, and companion diagnostic development for drug programs. Revenue from R&D collaboration fees, milestone payments, and potential royalties on companion diagnostics developed alongside drug programs.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise lab and healthcare provider licensing
HybridMulti-year contractPharmaceutical R&D and biomarker discovery collaboration

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Waiv product offering

Product offering

Core offering

Waiv develops and commercializes CE-IVD marked AI-powered precision diagnostic tests for oncology, analyzing digitized H&E and IHC whole slide images to deliver prognostic risk profiling, MSI screening, BRCA mutation prediction, and tertiary lymphoid structure detection. Its product suite includes the Destra SaaS platform, RlapsRisk BC (breast cancer prognosis), MSIntuit Suite/CRC (MSI screening), BRCAura (gBRCA mutation screening, research use), and TLS Detect (research-use deep learning tool). The company also provides biopharma R&D services for biomarker discovery and companion diagnostic development.

Product overview

Waiv is an AI precision testing company that has spun out from Owkin (formerly Owkin Dx), building on seven years of medical-AI research to deliver clinical-grade, AI-powered diagnostic tests for precision oncology. The company operates a platform-plus-products architecture centered on its Destra digital pathology platform, which delivers multiple clinically validated AI tests including RlapsRisk BC (breast cancer prognosis), MSIntuit Suite (MSI screening for colorectal, endometrial, and gastric cancers), BRCAura (gBRCA mutation screening), and TLS Detect (tertiary lymphoid structures detection). Products leverage foundation models trained on hundreds of thousands of histopathology images from an international data network spanning academic institutions, hospitals, and laboratories. The portfolio includes both CE-IVDR marked clinical diagnostics and research-use-only products, with commercial deployment via Destra's interoperable platform and partnerships with pharmaceutical companies including MSD, AstraZeneca, and Daiichi Sankyo for biomarker discovery and companion diagnostics.

Differentiator

Problem solved

Functional benefit

Brands

  • Destra: AI-native digital pathology platform built for clinical workflows that delivers Waiv's best-in-class AI precision tests into pathologists' hands.
  • RlapsRisk BC
  • MSIntuit Suite
  • BRCAura
  • TLS Detect

Products and services

  • Destra Platform AI-native digital pathology SaaS platform that delivers Waiv's AI precision tests (RlapsRisk BC, MSIntuit Suite, BRCAura) into pathologist workflows. Provides interoperable access via API and through integrations with Proscia, Roche Diagnostics, Sectra, and Tribun Health viewer/IMS systems, with clinically compliant outputs and scalable SaaS infrastructure.
  • RlapsRisk BC CE-IVDR marked AI precision test that predicts breast cancer relapse risk directly from standard digitized H&E histopathology slides and clinical data, delivering genomic-level risk profiling without extensive additional molecular testing. C-index of 0.81 vs 0.76 for clinical factors alone. For hospital pathology labs and breast cancer treatment decision-making.
  • MSIntuit Suite (including MSIntuit CRC) CE-IVDR marked AI-enabled MSI (Microsatellite Instability) screening test suite that operates on H&E stained slides across colorectal, endometrial, and gastric cancers. Sensitivity 0.96-0.98 and specificity 0.47-0.46, designed to rule out approximately half of non-MSI patients from further testing. For pathology labs needing rapid, scalable MSI pre-screening to accelerate access to targeted immunotherapies.
  • BRCAura RUO Research-use-only AI digital pathology test designed to identify germline BRCA1/2 mutations from routine histology slides of HR+/HER2- breast cancer. AUC of 80% with 93% sensitivity, able to rule out approximately 40% of patients unlikely to carry gBRCA mutations. For research and translational research use.
  • TLS Detect Deep learning software that detects Tertiary Lymphoid Structures (TLS) from digitized H&E whole slide images across tumor types. Sensitivity of 97% on external validation, providing prognostic insights and predictive biomarkers for immunotherapy response, delivered via PDF report and dynamic heatmap. For research use only.
  • Biopharma Solutions End-to-end computational pathology services for pharmaceutical and biotech partners covering biomarker discovery, tumor microenvironment analysis across H&E and IHC, AI-derived outcome prediction, and co-development of companion diagnostics for oncology drug and ADC programs. For pharmaceutical development teams seeking biomarker and patient stratification support.

Quantifiable outcome

  • RlapsRisk BC achieves C-index of 0.81 vs 0.76 for clinical factors alone, with cumulative sensitivity of 0.69 vs 0.63 and dynamic specificity of 0.80 vs 0.76 compared to clinical factors alone for 5-year MFS prediction.
  • +4 more outcomes

Companies that use Waiv

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Waiv technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability7 records

Feature8 records

Waiv partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core and minor.

  • Daiichi SankyocoreStrategic or Co-development Partner · 6 May 2026Collaboration under which Waiv applies its end-to-end computational pathology platform to Daiichi Sankyo's antibody-drug conjugate (ADC) program. Waiv will perform tumor microenvironment (TME) analysis across H&E and IHC stained samples, biomarker discovery, and outcome prediction aimed at identifying biomarkers of treatment response for early-phase clinical trial optimization.
  • OwkincoreStrategic or Co-development Partner · 27 February 2025Waiv spun out from Owkin as an independent company. Owkin retains a minority stake without operational governance involvement. Waiv remains a strategic partner in Owkin's patient validation ecosystem, leveraging Owkin's decade of foundational medical AI research, patient data network of over 800 hospitals, and hospital partnerships.
  • AstraZenecacoreStrategic or Co-development Partner · 2 October 2024Partnership to develop an AI gBRCA pre-screen solution for breast cancer, building on prior Owkin collaboration on BRCAura. AstraZeneca collaborated on BRCAura development to accelerate identification of BRCA mutations for targeted treatment decisions. Owkin's K Pro platform was used under a separate multi-year licensing agreement.
  • MSD (Merck & Co.)coreStrategic or Co-development Partner · 19 December 2023Collaboration agreement to develop and commercialize AI-powered digital pathology diagnostics for the EU market. Waiv collaborates with MSD to assess the clinical impact of MSIntuit CRC. MSD is an existing pharmaceutical partner for biomarker discovery and AI-guided precision testing.
  • Gustave RoussycoreStrategic or Co-development PartnerWorld-class cancer research institute in Villejuif, France, and co-developer of RlapsRisk BC and BRCAura. Gustave Roussy contributed patient data for RlapsRisk BC validation and BRCAura development. Part of Waiv's network of academic partners contributing to clinical validation studies.
  • Institut BergoniécoreStrategic or Co-development PartnerComprehensive Cancer Center in Bordeaux, France. Development partner for TLS Detect, contributing annotated data for deep learning model development. Also contributing data for MSI Pan-Tumor Dx project and clinical validation studies.
  • Institut CuriecoreStrategic or Co-development PartnerLeading French academic cancer research center in Paris. Academic partner in the RlapsRisk BC validation study under the Unicancer network. Contributed patient data for clinical validation of Waiv's diagnostic tests.
  • UnicancercoreStrategic or Co-development PartnerFrench academic cancer research network acting as data controller for the RlapsRisk BC validation study. Coordinates academic hospital data sharing across the French hospital network for Waiv's clinical validation studies.
  • 4baseCareminorStrategic or Co-development PartnerPrecision oncology research collaboration announced between Owkin and 4baseCare to advance inclusive precision oncology research, jointly pursuing research initiatives.

Scale indicators3 records

Recent moves7 records

Expansion highlights6 records

Waiv competitors and assessment

Company assessment

Direct peers

  • PathAI: PathAI develops AI-powered pathology diagnostics for oncology and provides biopharma services for biomarker discovery and clinical trial support, directly mirroring Waiv's dual clinical-product and pharma-services model with overlapping H&E-based biomarker targets.
  • Paige AI: Paige offers AI-based digital pathology products including FDA-cleared prostate cancer detection and enterprise pathology platforms; serves biopharma for biomarker and companion diagnostic development with similar foundation-model-based histology analysis to Waiv.
  • Ibex Medical Analytics: Ibex provides AI-powered cancer diagnostics deployed in clinical pathology workflows, including breast and prostate cancer detection, with similar H&E-based tissue analysis value proposition and integration with IMS systems.
  • ArteraAI: ArteraAI develops AI-based multimodal prostate cancer prognosis and treatment-decision tests from H&E slides with FDA clearances; directly comparable to Waiv's RlapsRisk BC breast cancer prognostic product in clinical AI biomarker prediction from routine pathology.
  • Proscia: Proscia is a digital pathology platform that distributes AI applications including Waiv's through its Concentriq IMS; comparable as both an integration channel and a competitor developing its own AI pathology applications.

Broad incumbents

  • Owkin: Owkin is Waiv's parent company, a broader AI biotech providing federated learning, drug discovery, and diagnostic services; retains minority stake in Waiv and remains its data and hospital network partner across oncology biomarkers.
  • Sectra: Sectra provides enterprise imaging and pathology IMS platforms used by hospitals; while a distribution partner for Waiv tests, its installed base and AI strategy position it as a broader incumbent in the pathology IT stack.
  • Tempus AI: Tempus operates a broad precision medicine platform combining molecular diagnostics, multimodal data, and AI for oncology; competes with Waiv's biopharma services and biomarker discovery offerings from a much larger installed base.
  • Roche Diagnostics: Roche is both a Waiv distribution partner and a major incumbent in IVD and digital pathology with the navify Digital Pathology platform; comparable as an established player whose installed base could either accelerate or compete with Waiv's AI tests.

Emerging players

  • Mindpeak: Mindpeak offers AI image analysis solutions for pathology including IHC quantification and biomarker scoring, with overlapping technology in tissue-based AI diagnostics; smaller scale than Waiv but directly competitive on certain use cases.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Waiv social profiles

Digital presence

Waiv compliance and trust

Trust signal

Compliance3 records

Waiv financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Waiv leadership team

Management profile

Number of profiles

Profiles2 records

Waiv funding detail

Funding detail

Funding overview

Funding rounds18 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Waiv M&A and investment

M&A and investment

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Waiv

What does Waiv do?

Waiv develops and commercializes CE-IVD marked AI-powered precision diagnostic tests for oncology, analyzing digitized H&E and IHC whole slide images to deliver prognostic risk profiling, MSI screening, BRCA mutation prediction, and tertiary lymphoid structure detection. Its product suite includes the Destra SaaS platform, RlapsRisk BC (breast cancer prognosis), MSIntuit Suite/CRC (MSI screening), BRCAura (gBRCA mutation screening, research use), and TLS Detect (research-use deep learning tool). The company also provides biopharma R&D services for biomarker discovery and companion diagnostic development.

Is Waiv a public or private company?

Waiv is a private company. It is classified as venture growth investor backed and is currently operating.

When was Waiv founded?

Waiv was founded in 2026. It employs 251 to 500 people.

Where is Waiv based?

Waiv is headquartered in New York, United States, in the North America region.

How does Waiv make money?

Two revenue lines are on record. Clinical diagnostic test licensing and deployment is the primary driver. The others are biopharma companion diagnostics and biomarker discovery partnerships.

Who are Waiv's main competitors?

Direct peers on record are PathAI, Paige AI, Ibex Medical Analytics, ArteraAI and Proscia. Broad incumbents are Owkin, Sectra, Tempus AI and Roche Diagnostics. Mindpeak is listed as an emerging player.

Does Waiv have an API?

Yes. Destra offers an API that enables integration of Waiv's AI precision tests into existing laboratory workflows. The API is designed to provide interoperable access to Waiv's digital pathology tests for routine or research purposes. Developer documentation is at wearewaiv.com/precision-testing/destra.

What industry is Waiv in?

Waiv's product category is Precision Oncology Digital Pathology AI Diagnostics. Its primary akta.pro industry code is HLAAALAI, Cytology & Histopathology Diagnostics (IHC, ISH, tissue-based assays), with a secondary code of HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy). Its NAICS code is 6215 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pharmaceutical TechnologyAstraZeneca, Daiichi Sankyo's Datroway receives FDA approval for TNBCAstraZeneca and Daiichi Sankyo received FDA approval for Datroway to treat metastatic triple-negative breast cancer in patients ineligible for PD-1/PD-L1 inhibitors. The first TROP2-directed ADC approval in this group, the drug extended median overall survival by five months and achieved a 64% objective response rate versus 30% with chemotherapy.StartupmagWaiV Robotics secures £5.53m seed to recover VTOLs with gyro-stabilised landing padWaiV Robotics raised £5.53m in seed funding to launch a gyro-stabilised landing and takeoff platform that recovers VTOL drones on moving vessels as small as 10 metres. The system automates launch and recovery in high sea states without aircraft modifications, targeting offshore inspection, windfarm maintenance, search and rescue, and defence. The company plans to scale down to 3kg aircraft and up to 100–300kg carrier classes.BioSpaceWaiv Enters Collaboration with Daiichi Sankyo to Deliver AI-Derived Biomarkers for ADC ProgramWaiv, formerly Owkin Dx, announced a collaboration with Daiichi Sankyo to apply its digital pathology platform to an antibody-drug conjugate program. The partnership aims to identify treatment-response biomarkers from H&E and IHC samples, targeting data-constrained settings with foundation models. Waiv's CEO said the collaboration reflects its end-to-end biomarker capability.Business Wire BlogWaiv Enters Collaboration with Daiichi Sankyo to Deliver AI-Derived Biomarkers for ADC ProgramWaiv announced a collaboration with Daiichi Sankyo to apply its AI-powered computational pathology platform to early-phase data for an antibody-drug conjugate program. The partnership aims to identify treatment-response biomarkers from H&E and IHC samples, targeting data-constrained settings with fewer than 100 patients.Via TTWaiv Achieves Dual CE Marking Under IVDR, Propelling AI Precision Testing for Breast and Colorectal Cancer for Clinical RoutineWaiv (formerly Owkin Dx) announced that its two AI precision tests, RlapsRisk BC for breast cancer prognostic risk profiling and MSIntuit CRC for colorectal cancer MSI screening, have each received CE marking under the European In Vitro Diagnostic Regulation, authorizing clinical deployment across EU member states. IVDR certification requires extensive clinical evidence, robust performance validation, and continuous post-market oversight, representing a rigorous regulatory milestone. The tests enable risk profiling from standard histopathology slides and rapid MSI screening to support personalized treatment decisions in oncology practice.WebcapitalriesgoWaiv cierra $35M de financiación total con una nueva inversión de CRB Health TechWaiv closed a $35 million Series A funding round led by CRB Digital Health III, with participation from business angels. The funds will support clinical deployment and commercial expansion of its AI-based precision oncology tests. The company also recently received CE marking under IVDR for two of its tests.Empresas de Capital Riesgo en EspaWaiv closes $35 million in total funding with a new investment from CRB Health TechWaiv closed a $35 million Series A funding round led by CRB Digital Health III, with participation from OTB Ventures and Alpha Intelligence Capital. The company also secured CE marking under the IVDR for two AI-powered precision tests, RlapsRisk BC and MSIntuit CRC. The capital will support expansion across laboratories and strengthen commercial traction.Business Wire BlogWaiv Achieves Dual CE Marking Under IVDR, Propelling AI Precision Testing for Breast and Colorectal Cancer for Clinical RoutineWaiv announced that its AI precision tests RlapsRisk BC for breast cancer and MSIntuit CRC for colorectal cancer MSI screening received CE marking under the European IVDR, authorizing clinical use across EU member states. The tests enable genomic-level risk profiling and rapid MSI screening from H&E slides, aiming to streamline workflows and accelerate access to targeted treatments.MedCity NewsStartup Waiv Spins Out of Owkin With $33M to Bring AI Precision to Cancer DecisionsParis-based AI diagnostics startup Waiv has spun out from its parent company Owkin and raised $33 million in funding led by OTB Ventures and Alpha Intelligence Capital. The company uses artificial intelligence to analyze digital pathology images, helping clinicians make more precise cancer treatment decisions. Waiv will use the new capital to expand its clinical testing offerings and support commercial expansion globally.European BiotechnologyOwkin spins out AI diagnostics startup Waiv with $33M financingFrench AI biotech Owkin has spun out its diagnostics division as a new independent company called Waiv, raising $33 million in financing led by OTB Ventures and Alpha Intelligence Capital. The Paris-based startup will develop AI-powered precision diagnostics, including tools for identifying cancer biomarkers and stratifying patients for clinical trials and treatment decisions. As part of Owkin's strategy to build specialized independent businesses, Waiv will operate autonomously while maintaining strategic ties to the parent company's hospital partnerships and biomedical datasets.